Your session is about to expire
← Back to Search
Monoclonal Antibodies
DLX105-DMP Multi-Dose Twice Weekly for Plaque Psoriasis
Phase 1
Waitlist Available
Research Sponsored by DelArrivo, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 15, and day 25
Awards & highlights
Summary
This trial tests DLX105-DMP on patients with mild-to-moderate plaque psoriasis to see if applying it to the skin can reduce symptoms like redness and scaliness.
Eligible Conditions
- Plaque Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1, day 15, and day 25
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 15, and day 25
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events
Local Investigator Global Assessment (IGA)
Local Psoriasis Area Severity Index Sum of Scores (Local PASI SOS)
+2 moreSecondary study objectives
Immunogenicity Testing
Pharmacokinetic Parameters
Trial Design
2Treatment groups
Experimental Treatment
Group I: DLX105-DMP Multi-Dose Twice WeeklyExperimental Treatment1 Intervention
4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly
Group II: DLX105-DMP Multi-Dose Once WeeklyExperimental Treatment1 Intervention
4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DLX105-DMP
2022
Completed Phase 1
~10
Find a Location
Who is running the clinical trial?
DelArrivo, Inc.Lead Sponsor
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger